Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID

Medicines For Europe And IGBA Set Out Policy Priorities At Athens Conference

 
• By Dave Wallace
  
Lens Focus Light Focal Point
Generics and biosimilars must be a “focal point” for health systems • Source: Alamy

More from Policy & Regulation

More from Generics Bulletin